Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated Angiogenesis

Patent No. EP3351246 (titled "Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated Angiogenesis") was filed by Novartis on Feb 18, 2002. The application was issued on Sep 18, 2019.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (9)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3351246

NOVARTIS
Application Number
EP18155644A
Filing Date
Feb 18, 2002
Status
Revoked
Oct 23, 2023
Publication Date
Sep 18, 2019